Monday, August 28, 2006

PolyHeme - Dracula's Holy Grail?

Northfield Laboratories, Inc., has completed a Phase III trial for Polyheme, its oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss and has applied for the Federal Drug Administration's Fast-Track status.

Northfield has been researching blood substitutes for more than twenty years posting over $170 million in losses in its pursuit of Dracula's Holy Grail.

Northfield's annual meeting is September 20, 2006. A recent news release linked here.

Northfield's website linked here.

An interesting article linked here.

No comments:

Personal Blogs - Blog Top Sites